Cargando…
The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
BACKGROUND: Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose combination (FDC) of two active antiemetic agents in...
Autores principales: | Vaswani, Bharat, Dattatreya, Palanki Satya, Bhagat, Sagar, Patil, Saiprasad, Barkate, Hanmant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145828/ https://www.ncbi.nlm.nih.gov/pubmed/34034703 http://dx.doi.org/10.1186/s12885-021-08342-1 |
Ejemplares similares
-
The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022) -
Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
por: Vaswani, Bharat, et al.
Publicado: (2020) -
Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective
por: Vaid, Ashok K., et al.
Publicado: (2020) -
ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
por: Sahoo, Tarini Prasad, et al.
Publicado: (2023) -
Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
por: Desai, Chirag, et al.
Publicado: (2022)